Effects of statins on functional capacity and cardiac remodeling in patients with heart failure and preserved ejection fraction: a randomized open-label pilot trial - Takeaways - MDSpire

Effects of statins on functional capacity and cardiac remodeling in patients with heart failure and preserved ejection fraction: a randomized open-label pilot trial

  • By

  • Artem Ovchinnikov

  • Alexandra Potekhina

  • Olga Svirida

  • Tatiana Arefieva

  • Tamila Martynyuk

  • Fail Ageev

  • Marijana Tadic

  • Evgeny Belyavskiy

  • July 13, 2026

Share

  • 1

    The study evaluated the effects of atorvastatin and rosuvastatin on heart failure with preserved ejection fraction (HFpEF) in 59 patients.

  • 2

    Atorvastatin showed a greater increase in 6-minute walk distance compared to rosuvastatin after 6 months of therapy.

  • 3

    Both statin groups demonstrated comparable improvements in NYHA functional class and diastolic function.

  • 4

    Atorvastatin significantly decreased inflammatory biomarkers, while rosuvastatin showed reductions only in specific patient subgroups.

  • 5

    The study suggests atorvastatin may provide additional benefits over rosuvastatin in modifying cardiac function in HFpEF patients.

Original Source(s)

Effects of statins on functional capacity and cardiac remodeling in patients with heart failure and preserved ejection fraction: a randomized open-label pilot trial

  • by Artem Ovchinnikov, Alexandra Potekhina, Olga Svirida, Tatiana Arefieva, Tamila Martynyuk, Fail Ageev, Marijana Tadic, Evgeny Belyavskiy

  • July 13, 2026

Related Content

Insulin resistance as a predictor of long-term adverse cardiovascular event risk in patients with atrial fibrillation following radiofrequency catheter ablation

Myocardial work abnormalities in rheumatoid arthritis with preserved left ventricular ejection fraction are more closely related to disease activity than to disease duration: a prospective cross-sectional study

Patterns of temporary mechanical circulatory support, escalation, de-escalation and outcomes in cardiogenic shock